Mounjaro vs Zepbound

If you've heard people talk about Mounjaro and Zepbound as if they were different drugs, here's the short version: they aren't. Both are tirzepatide, both are made by Eli Lilly, both are once-weekly subcutaneous injections, and both come in the same dose strengths (2.5, 5, 7.5, 10, 12.5, and 15 mg).

The difference lives on the label. Mounjaro is FDA approved for type 2 diabetes. Zepbound is FDA approved for chronic weight management and, more recently, moderate-to-severe obstructive sleep apnea in adults with obesity. That regulatory split changes which condition can be billed to insurance, who can be prescribed it, and how the manufacturer markets each version.

For patients, the practical question is rarely "which works better" (they are the same drug) but "which one will my prescriber and my insurer agree to."

At a glance

How they're alike

The molecule is identical. Mounjaro and Zepbound contain the same tirzepatide, in the same pen device, at the same six dose strengths. The injection schedule is the same: once weekly, on any day, with or without food. The same gradual titration applies: typically a 2.5 mg starter dose for four weeks, then stepwise increases to a maintenance dose of 5, 10, or 15 mg as tolerated.

Side effects are the same family because the drug is the same: nausea, constipation, diarrhea, decreased appetite, and fatigue lead the list. The boxed warning about thyroid C-cell tumors (carried over from animal data) appears on both labels.

Weight loss potential is also fundamentally the same. The biology does not care which name is printed on the pen. People taking 15 mg of Mounjaro for diabetes often see weight reductions in the same range as people taking 15 mg of Zepbound for obesity, when other factors line up.

How they're different

The FDA-approved indication is the cleanest difference. Mounjaro is licensed for type 2 diabetes; Zepbound is licensed for chronic weight management (and now obstructive sleep apnea in adults with obesity). That means clinicians prescribe Mounjaro to people with a diabetes diagnosis and Zepbound to people seeking the obesity indication. Off-label prescribing exists but complicates prior authorizations.

Insurance behavior tracks the label. Many plans cover Mounjaro for documented type 2 diabetes but exclude it for weight loss; many plans either cover Zepbound for obesity or exclude weight loss drugs entirely. People who pay out of pocket sometimes find the Lilly self-pay programs more favorable for one brand than the other.

Marketing and savings programs differ too. Eli Lilly runs separate patient assistance and savings card programs for each brand, and supply has occasionally been tight for one while the other was available. Pharmacies treat them as separate NDCs even though the contents are the same.

Which one is right for you?

The diagnosis usually decides it. If you have type 2 diabetes, Mounjaro is the on-label option. If your goal is weight loss without diabetes, Zepbound is the on-label option. Both deliver the same tirzepatide, so the choice is not about effectiveness but about coverage and access.

Talk with your prescriber about three things: what your insurance will actually pay for, which brand the pharmacy has in stock, and which manufacturer savings program you qualify for. Switching between the two during treatment is generally straightforward because they are the same molecule at the same doses — but you should never switch without medical guidance.

Common questions

Keep exploring

Browse all GLP-1 guides or read Wegovy vs Zepbound for the most common weight-loss decision.